An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer
NCT ID: NCT04492293
Last Updated: 2024-02-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
115 participants
INTERVENTIONAL
2020-05-27
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
NCT06108492
Adjuvant Intraarterial Chemotherapy Following Surgery to Treat Locally Advanced Bladder Cancer
NCT01627197
Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer
NCT05445648
Identifying Methylation Biomarkers for Monitoring Bladder Tumors
NCT00244205
Research on the Combined-Modality Treatment Model of Bladder Preservation in Muscular Invasive Bladder Cancer
NCT02861196
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ICP-192
ICP-192
ICP-192
ICP-192 is a white, round, uncoated table
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ICP-192
ICP-192 is a white, round, uncoated table
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. ECOG ≤ 1.
3. Life expectancy of at least 3 months.
4. Histologically confirmed unresectable or metastatic bladder urothelial cancinoma.
5. At least one measurable lesion as the target lesion at screening assessed according to RECIST V1.1
Exclusion Criteria
2. Any corneal or retinal abnormalities that may result in an increased risk of ocular toxicity.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing InnoCare Pharma Tech Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jun Guo
Role: PRINCIPAL_INVESTIGATOR
Peking University Cancer Hospital & Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Peking University First Hospital
Beijing, Beijing Municipality, China
The fifth Medical Center of People's Liberation Army General Hospital
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Lanzhou University Second Hospital
Lanzhou, Gansu, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
The First Affiliated Hospital of Suzhou University
Suzhou, Jiangsu, China
The First Hospital of JiLin University
Jilin, Jilin, China
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China
Shandong University Qilu Hospital
Jinan, Shandong, China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Sichuan Cancer Hospital
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
The Second Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejing, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Chaozhao Liang
Role: primary
Zisong He
Role: primary
Lijun Chen
Role: primary
Weiyang He
Role: primary
Li Yang
Role: primary
Hui Chen
Role: primary
Xiaoping Zhang
Role: primary
Shaogang Wang
Role: primary
Weiqing Han
Role: primary
Yuhua Huang
Role: primary
Ziling Liu
Role: primary
Bin Hu
Role: primary
Benkang Shi
Role: primary
Danfeng Xu
Role: primary
Xiaoming Cao
Role: primary
Liao Hong
Role: primary
Xin Yao
Role: primary
Hailong Hu
Role: primary
Liping Xie
Role: primary
Shaoxing Zhu
Role: primary
Haiying Dong
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICP-CL-00302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.